Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{ [(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({ (1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl} carbamoyl)pyrrolidin-1-yl]carbonyl} -2,2-dimethylpropyl]carbamate
The present disclosure includes various embodiments directed to a solubilised capsule formulation of asunaprevir, 1,1-dimethylethyl [(1S)-1-{ [(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({ (1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl} carbamoyl)pyrr olidin-1-yl]carbonyl} -...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The present disclosure includes various embodiments directed to a solubilised capsule formulation of asunaprevir, 1,1-dimethylethyl [(1S)-1-{ [(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({ (1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl} carbamoyl)pyrr olidin-1-yl]carbonyl} -2,2-dimethylpropyl]carbamate, and to methods of treating hepatitis C virus (HVC) infection. The formulations are solubilised by medium-chain fatty acid triglycerides, combinations of mono, di and triglycerides of long-chain fatty acids; mono- and di- long-chain fatty acid esters of polyethylene glycol (commonly known as polyoxyethylated glycerides, i.e., oleoyl polyoxylglycerides and linoleoyl polyoxylglycerides); glycerol monocaprylocaprate, glycerol monocaprylate, glycerol mono/dicaprate, and the propylene glycol mono- and diesters of medium-chain fatty acids such as propylene glycol monocaprylate, propylene glycol monolaurate, propylene glycol dilaurateand, and combinations thereof. |
---|